Oncology

• 

  All Medical News

  For grade 2 glioma, radiation plus chemo betters radiation alone

  Written by Bruce Sylvester | 26 Apr 2016

  by Bruce Sylvester: Patients with grade 2 glioma who received radiation therapy plus PCV chemotherapy (procarbazine, lomustine and vincristine) have achieved longer progression-free survival and overall survival than… read more.

• 

  All Medical News

  World Health Matters: Italy: Leukaemia death rate expected to fall in 2016

  Written by Gary Finnegan | 22 Feb 2016

  by Gary Finnegan: Good news in the battle against cancer: death rates from leukaemia among people of all ages in Europe are falling.

• 

  All Medical News

  ASH 2015: Building good combinations. Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) discusses the benefits of building good combinations early on in therapy and the impact that newly available triplet oral therapy will have on patients with myeloma

  Written by Lorraine Carolan | 15 Feb 2016

• 

  All Medical News

  ASH 2015: Good news for patients from ASH! Erik Low (Chief Executive Myeloma UK), Professor Antonio Palumbo (University of Torino, Italy), Professor Paul Richardson (Harvard Medical School, Boston, USA) and Dr Shaji Kumar (Mayo Clinic, Rochester, USA) discuss the things they will take home to their myeloma patients folloing ASH 2015

  Written by Lorraine Carolan | 12 Feb 2016

• 

  All Medical News

  ASH 2015: Video Interview by Esther Drain. CDF changes affecting myeloma patients. Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Erik Low (Chief Executive Myeloma UK) discuss recent changes in the CDF and how they affect myeloma patients.

  Written by Lorraine Carolan | 11 Feb 2016

• 

  All Medical News

  ASH 2015: We ask Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) what the role of PET/CT is as a measure of MRD post ASCT and ask Professor Antonio Palumbo (University of Torino, Italy) and Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) whether MRD measurement is ready for clinical use

  Written by Lorraine Carolan | 10 Feb 2016

  Role of minimal residual disease in treatment tailoring divides experts by Thomas R. Collins Minimal residual disease (MRD) is a guide for tailoring multiple myeloma whose time has… read more.

• 

  All Medical News

  ASH 2015: Video Interview by Esther Drain. Myeloma XI initial response data at ASH. Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) discusses the initial response data from Myeloma XI and whether early intensive therapy is the way forward in managing myeloma, with comment also from Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA).

  Written by Lorraine Carolan | 9 Feb 2016

• 

  All Medical News

  ASH 2015: Myeloma X (intensive) trial update: Professor Gordon Cook (Leeds Teaching Hospitals, UK) gives an update on Myeloma X and discusses the role of transplant in myeloma in the age of novel agents

  Written by Lorraine Carolan | 5 Feb 2016

• 

  All Medical News

  ASH 2015: Professor Antonio Palumbo (University of Torino, Italy), Dr Shaji Kumar (Mayo Clinic, Rochester, USA), Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Professor Gordon Cook (Leeds Teaching Hospitals, UK) give their highlights.

  Written by Lorraine Carolan | 4 Feb 2016

• 

  All Medical News

  ASH 2015 Video Interview by Esther Drain: Association of gene expression profiling, Interim PET, EBV status and PD-L1 expression in cHL. An interview with Dr Cathy Burton (Clinical Haematologist, Leeds Teaching Hospitals, UK)

  Written by Lorraine Carolan | 27 Jan 2016

• 

  All Medical News

  ASH 2015 Video Interview by Esther Drain: Is oral as effective as IV or sub cutaneous administration? Professor Philippe Moreau (University Hospital, Nantes, France), Professor Gordon Cook (Leeds Teaching Hospitals, UK) and Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) discuss whether the trend towards new oral agents for myeloma will mean a choice between efficacy and convenience… or in fact whether both can be achieved

  Written by Lorraine Carolan | 26 Jan 2016

• 

  All Medical News

  ASH 2015: TOURMALINE: Professor Philippe Moreau (University Hospital, Nantes, France) discusses the Tourmaline study – ixazomib, lenalidomide, dexamethasone (iRd) in R/R myeloma, with opinions on the data from Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK), Professor Gordon Cook (Leeds Teaching Hospitals, UK), Erik Low (Chief Executive Myeloma UK) and Dr Shaji Kumar (Mayo Clinic, Rochester, USA)

  Written by Lorraine Carolan | 25 Jan 2016

  Ixazomib improves progression-free survival across subgroups by Thomas R. Collins: The oral proteasome inhibitor (PI) ixazomib with lenalidomide and dexamethasone (IRd) performed well versus placebo plus lenalidomide and… read more.